Sebastian Sylvestre1, Timothy Craig1, Oyindamola Ajewole2, Sansanee Craig3, Sundeep Kaur1, Taha Al-Shaikhly4. 1. Section of Allergy, Asthma and Immunology, Department of Medicine, Penn State University, Hershey, Pa. 2. Department of Pediatrics, Penn State University, Hershey, Pa. 3. Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pa. 4. Section of Allergy, Asthma and Immunology, Department of Medicine, Penn State University, Hershey, Pa. Electronic address: talshaikhly@pennstatehealth.psu.edu.
Abstract
BACKGROUND: Hereditary angioedema (HAE) affects all races and both sexes equally. Minority patients are underrepresented in clinical trials and may be at risk for additional disease burden. OBJECTIVES: To examine racial and ethnic disparities in the research and care of patients with HAE. METHODS: We conducted a retrospective population-based study using TriNetX Diamond Network. International Classification of Diseases, 10th Revision, Current Procedural Terminology, and RxNorm codes identified patients with HAE. The proportions of White, Black, and Hispanic patients with HAE were contrasted with racial and ethnic distributions of patients with HAE in clinical trials. Lifetime prevalence of mental health disorders and HAE treatments was contrasted among different racial and ethnic groups. RESULTS: A population-based search identified 2122 patients with HAE. The prevalence of HAE among Black patients (1.64/100,000 patients) mirrored that of White patients (1.47/100,000 patients), whereas there was a lower HAE prevalence among Hispanic patients (0.80/100,000 patients). The demographics of the 1274 patients with HAE included in phase 2/3 clinical trials differed significantly from population-based data with overrepresentation of White patients (89.9% vs 77.9%) and underrepresentation of Black patients (3.8% vs 13.6%) and Hispanic patients (1.3% vs 8.1%). Across the different racial and ethnic groups of patients with HAE, the prevalence of mental health disorders was comparatively higher than among patients without HAE. Whereas depression was equally prevalent across the different HAE racial and ethnic groups, anxiety was more prevalent among White patients. CONCLUSIONS: Clinical trials for Food and Drug Administration-approved HAE medications underrepresent minority patients. Hereditary angioedema remains underdiagnosed in Hispanic patients. Other than a lower prevalence of anxiety disorders among Black patients relative to White patients, the mental health impact of HAE is equally distributed across the different racial and ethnic groups.
BACKGROUND: Hereditary angioedema (HAE) affects all races and both sexes equally. Minority patients are underrepresented in clinical trials and may be at risk for additional disease burden. OBJECTIVES: To examine racial and ethnic disparities in the research and care of patients with HAE. METHODS: We conducted a retrospective population-based study using TriNetX Diamond Network. International Classification of Diseases, 10th Revision, Current Procedural Terminology, and RxNorm codes identified patients with HAE. The proportions of White, Black, and Hispanic patients with HAE were contrasted with racial and ethnic distributions of patients with HAE in clinical trials. Lifetime prevalence of mental health disorders and HAE treatments was contrasted among different racial and ethnic groups. RESULTS: A population-based search identified 2122 patients with HAE. The prevalence of HAE among Black patients (1.64/100,000 patients) mirrored that of White patients (1.47/100,000 patients), whereas there was a lower HAE prevalence among Hispanic patients (0.80/100,000 patients). The demographics of the 1274 patients with HAE included in phase 2/3 clinical trials differed significantly from population-based data with overrepresentation of White patients (89.9% vs 77.9%) and underrepresentation of Black patients (3.8% vs 13.6%) and Hispanic patients (1.3% vs 8.1%). Across the different racial and ethnic groups of patients with HAE, the prevalence of mental health disorders was comparatively higher than among patients without HAE. Whereas depression was equally prevalent across the different HAE racial and ethnic groups, anxiety was more prevalent among White patients. CONCLUSIONS: Clinical trials for Food and Drug Administration-approved HAE medications underrepresent minority patients. Hereditary angioedema remains underdiagnosed in Hispanic patients. Other than a lower prevalence of anxiety disorders among Black patients relative to White patients, the mental health impact of HAE is equally distributed across the different racial and ethnic groups.
Authors: Michael E Wechsler; Stanley J Szefler; Victor E Ortega; Jacqueline A Pongracic; Vernon Chinchilli; John J Lima; Jerry A Krishnan; Susan J Kunselman; David Mauger; Eugene R Bleecker; Leonard B Bacharier; Avraham Beigelman; Mindy Benson; Kathryn V Blake; Michael D Cabana; Juan-Carlos Cardet; Mario Castro; James F Chmiel; Ronina Covar; Loren Denlinger; Emily DiMango; Anne M Fitzpatrick; Deborah Gentile; Nicole Grossman; Fernando Holguin; Daniel J Jackson; Harsha Kumar; Monica Kraft; Craig F LaForce; Jason Lang; Stephen C Lazarus; Robert F Lemanske; Dayna Long; Njira Lugogo; Fernando Martinez; Deborah A Meyers; Wendy C Moore; James Moy; Edward Naureckas; J Tod Olin; Stephen P Peters; Wanda Phipatanakul; Loretta Que; Hengameh Raissy; Rachel G Robison; Kristie Ross; William Sheehan; Lewis J Smith; Julian Solway; Christine A Sorkness; Lisa Sullivan-Vedder; Sally Wenzel; Steven White; Elliot Israel Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: Fernando D Martinez; Vernon M Chinchilli; Wayne J Morgan; Susan J Boehmer; Robert F Lemanske; David T Mauger; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Elizabeth Bade; Ronina A Covar; Noah J Friedman; Theresa W Guilbert; Hengameh Heidarian-Raissy; H William Kelly; Jonathan Malka-Rais; Michael H Mellon; Christine A Sorkness; Lynn Taussig Journal: Lancet Date: 2011-02-14 Impact factor: 79.321
Authors: Marc A Riedl; Robyn J Levy; Daniel Suez; Richard F Lockey; James W Baker; Anurag Relan; Bruce L Zuraw Journal: Ann Allergy Asthma Immunol Date: 2013-03-06 Impact factor: 6.347
Authors: Susan J Kim; Jordan C Brooks; Javed Sheikh; Michael S Kaplan; Bruce J Goldberg Journal: Ann Allergy Asthma Immunol Date: 2014-10-03 Impact factor: 6.347
Authors: Timothy J Craig; Rafael H Zaragoza-Urdaz; H Henry Li; Ming Yu; Hong Ren; Salomé Juethner; John Anderson Journal: Allergy Asthma Clin Immunol Date: 2022-09-24 Impact factor: 3.373